Compare ARDX & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | BLMN |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.8M | 975.2M |
| IPO Year | 2014 | 2012 |
| Metric | ARDX | BLMN |
|---|---|---|
| Price | $3.83 | $10.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $15.14 | $7.88 |
| AVG Volume (30 Days) | ★ 4.8M | 2.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.99% |
| EPS Growth | N/A | ★ 106.71 |
| EPS | N/A | ★ 1.01 |
| Revenue | $2,607,000.00 | ★ $4,213,346,000.00 |
| Revenue This Year | $37.75 | $2.07 |
| Revenue Next Year | $34.24 | $1.81 |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.73 | $5.19 |
| 52 Week High | $8.40 | $12.63 |
| Indicator | ARDX | BLMN |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 54.47 |
| Support Level | N/A | $10.14 |
| Resistance Level | $6.47 | $12.63 |
| Average True Range (ATR) | 0.14 | 0.59 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 12.33 | 34.37 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.